Celgene appoints former Cubist chief executive

pharmafile | April 20, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, cubist, michael bonney 

Celgene has elected pharma veteran Michael Bonney to join its board of directors.

Bonney served as chief executive and board member of Cubist Pharmaceuticals from 2003 until his retirement in December last year.

Prior to this, Bonney’s healthcare experience includes serving as president and chief operating officer at Cubist in 2002, and holding various positions at Biogen from 1995 to 2001. He also worked in sales, marketing and strategic planning at Zeneca Pharmaceuticals over an 11-year period.

Bonney currently serves as a director of Alnylam Pharmaceuticals, and was a director of NPS Pharmaceuticals from 2005 until its sale to Shire ten years later.

“Mike’s extensive leadership and operational experience will help guide us as we execute our key strategic imperatives,” says Bob Hugin, Celgene chairman and chief executive. “Celgene will benefit greatly from Mike’s knowledge and insights on the increasingly dynamic global healthcare environment.”

Related Content


NICE recommends Celgene’s REVLIMID for multiple myeloma

NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment …

NICE opts to reject Celgene’s Revlimid for newly diagnosed multiple myeloma after an autologous stem cell transplant

It has emerged that NICE has opted to reject Celgene’s Revlimid (lenalidomide) for the maintenance …


NICE recommends Celgene’s Revlimid combo for follicular lymphoma

NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has …

Latest content